

ASX ANNOUNCEMENT
7 March 2022



CLEANSING NOTICE

NOTICE PURSUANT TO PARAGRAPH 708A(5)(e) OF THE CORPORATIONS ACT 2001

This notice is given by Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (“Act”).

The Company advises that on 7 March 2022 it applied for quotation of 4,000,000 fully paid ordinary shares on the conversion of 3,500,000 options exercisable at \$0.30 each and 500,000 vested performance rights as detailed in the ASX announcement dated the same day.

LGP gives notice that:

1. the Shares were issued without disclosure under Part 6D.2 of the Corporations Act;
2. as at the date of this notice the Company has complied with:
 - i. the provision of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. section 674 of the Corporations Act; and
3. as at the date of this notice there is no excluded information required to be disclosed under section 708A(6)(e) of the Corporations Act.

Notwithstanding this, LGP notes that in its ordinary course of business, it is continually working with prospective customers and potential suppliers, acquirers and targets on active proposals including supply, offtake, disposal and acquisition proposals, some of which may, in the future, prove to be material and potentially price sensitive. In the event that any such proposals become sufficiently certain or material enough to warrant disclosure to the market, the Company will comply with its disclosure obligations at that time.

ENDS

BY ORDER OF THE BOARD

A handwritten signature in dark ink, appearing to be "Alistair Warren", written over a horizontal line.

Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren, Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon, Chief Executive Officer
Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 20 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

